vepalimomab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 470629578

| image =

| type = mab

| mab_type = mab

| source = o

| target = VAP-1

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 195158-85-1

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 0M19J59UH4

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| chemical_formula =

| molecular_weight =

}}

Vepalimomab is an experimental mouse monoclonal antibody intended for the treatment of inflammations. It blocks vascular adhesion protein 1.{{cite journal | vauthors = Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T | title = Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis | journal = Basic & Clinical Pharmacology & Toxicology | volume = 96 | issue = 6 | pages = 429–35 | date = June 2005 | pmid = 15910406 | doi = 10.1111/j.1742-7843.2005.pto_05.x | doi-access = free }} Development of the drug was discontinued in 2002.{{cite web |title=Vepalimomab | work = AdisInsight |url=https://adisinsight.springer.com/drugs/800016990 | publisher = Springer Nature Switzerland AG }}